Fosaprepitant dimeglumine (Nausap Iv)

Fosaprepitant dimeglumine

Dr Reddyæs Laboratories (Pty) Ltd

Registration

Applicant: Dr Reddyæs Laboratories (Pty) Ltd
Certificate holder: Dr Reddy’s Laboratories (Pty) Ltd
Registrations: 1

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Nausap 150 iv FOSAPREPITANT DIMEGLUMINE	150 mgLyophilised powder for solution for infusion	53045853/5.7.2/0458Approved 15 November 2022	Registered	Not determined	PI PIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C₂₃H₂₂F₇N₄O₆P614.40 g/mol

[3-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-5-oxo-4H-1,2,4-triazol-1-yl]phosphonic acid

Drag to rotate. Structure from PubChem CID 135413538.

SAHPRA documents

Professional information (PI)For healthcare professionals Patient information leaflet (PIL)For patients and carers

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading Wikipedia summary

Research articles

Loading PubMed articles